Endorepellin/Perlecan/Heparan Sulfate Proteoglycan Antibody (A7L6), Alexa Fluor™ 594, Novus Biologicals™

Rat Monoclonal Antibody

Supplier:  Novus Biologicals NBP247695AF594

Catalog No. NB007170

Description

Endorepellin/Perlecan/Heparan Sulfate Proteoglycan Monoclonal specifically detects Endorepellin/Perlecan/Heparan Sulfate Proteoglycan in Human, Mouse, Porcine, Bovine, Fish, Monkey samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence.

Specifications

• Antigen: Endorepellin/Perlecan/Heparan Sulfate Proteoglycan
• Classification: Monoclonal
• Conjugate: Alexa Fluor 594
• Formulation: 50mM Sodium Borate with 0.05% Sodium Azide
• Gene Symbols: HSPG2
• Immunogen: Murine EHS laminin preparation
• Quantity: 0.1 mL
• Primary or Secondary: Primary
• Target Species: Human, Mouse, Porcine, Fish, Monkey
• Isotype: IgG2a κ

• Applications: Flow Cytometry, Immunohistochemistry, Immunohistochemistry (Paraffin), Immunofluorescence
• Clone: A7L6
• Dilution: Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunofluorescence
• Gene Alias: basement membrane-specific heparan sulfate proteoglycan core protein, endorepellin (domain V region), heparan sulfate proteoglycan 2, HSPG, perlecan, perlecan proteoglycan, PLCSchwartz-Jampel syndrome 1 (chondrodystrophic myotonia), PRCAN, SJA, SJS, SJS1
• Host Species: Rat
• Purification Method: Protein A or G purified
• Regulatory Status: RUO
• Test Specificity: This monoclonal antibody specifically precipitates heterogeneous material of high MW, identified as perlecan, a major heparan-sulfate proteoglycan (HSPG) within all basement membranes and cell surfaces. It does not cross-react with laminin, fibronectin, or dermatran sulfate proteoglycan. Because of perlecans strategic location and ability to store and protect growth factors, it has been strongly implicated in the control of tumor cell growth and metastatic behavior. Perlecan possesses angiogenic and growth-promoting attributes primarily by acting as a co-receptor for basic fibroblast growth factor (FGF-2). Suppression of perlecan causes substantial inhibition of neoplastic growth and neovascularization. Thus, perlecan is a potent inducer of neoplasm growth and angiogenesis in vivo and therapeutic interventions targeting this key modulator of tumor progression may improve neoplastic treatment.
• Content And Storage: Store at 4°C in the dark.